N
Nkarta, Inc. (NKTX)
NMS – Real Time Price. Currency in USD
2.83
+0.05 (1.80%)
At close: Jun 26, 2026, 4:00 PM EDT
2.81
-0.02 (-0.71%)
After-hours: Jun 26, 2026, 6:13 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.83
+0.05 (1.80%)
At close: Jun 26, 2026, 4:00 PM EDT
2.81
-0.02 (-0.71%)
After-hours: Jun 26, 2026, 6:13 PM EDT
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Nadir Mahmood Ph.D. | President and Principal Accounting & Financial Officer |
| Dr. Shawn Rose M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
| Mr. Paul J. Hastings | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-06-11 | 8-K | nktx-20260610.htm |
| 2026-05-12 | 8-K | nktx-20260512.htm |
| 2026-05-12 | 10-Q | nktx-20260331.htm |
| 2026-04-23 | DEF 14A | ny20064125x1_def14a.htm |
| 2026-04-23 | ARS | ny20064125x3_ars.pdf |
| 2026-04-01 | CORRESP | filename1.htm |
| 2026-03-26 | 8-K | nktx-20260325.htm |
| 2026-03-25 | S-3 | ny20068088x1_s3.htm |
| 2026-03-25 | 10-K | nktx-20251231.htm |
| 2026-01-05 | S-8 | nktx-20260105.htm |